Ntla stock zacks
Stock Summary - TD Ameritrade Nov 07, 2019 · The volatility of a stock over a given time period. It is calculated by determining the average standard deviation from the average price of the stock over one month or 21 business days. Historical volatility can be compared with implied volatility to determine if a stock's options are over- … NTLA | Stock Snapshot - Fidelity Apr 03, 2020 · Stock quote and company snapshot for INTELLIA THERAPEUTICS INC (NTLA), including profile, stock chart, recent news and events, analyst opinions, and research reports. Zacks Investment Research Lowers Intellia Therapeutics ... Zacks Investment Research cut shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a sell rating in a report published on Saturday morning, Zacks.com reports. According to Zacks, “Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system.
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops ...
NTLA Stock | INTELLIA THERAPEUTICS Stock Price Today ... NTLA: Get the latest Intellia Therapeutics stock price and detailed information including NTLA news, historical charts and realtime prices. NTLA Intellia Therapeutics — Stock Price and Discussion ... Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures. Intellia Therapeutics Stock Quote: NTLA Stock News, Quotes ... Nov 08, 2019 · NTLA, Intellia Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines
Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to ...
Apr 07, 2020 · Intellia Therapeutics Inc (NASDAQ:NTLA)’s share price rose 6% during trading on Monday . The company traded as high as $12.72 and last traded at $12.71, approximately 480,287 shares changed hands during trading. A decline of 35% from the average daily volume of 743,192 shares. The stock had previously closed at $11.99. NTLA has been the […] Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops ... Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.43 per share a year ago. NTLA Intellia Therapeutics, Inc. Stock Quote Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. NTLA | Intellia Therapeutics Inc. Profile | MarketWatch Nov 05, 2019 · Intellia Therapeutics Inc. company facts, information and stock details by MarketWatch. View ntla business summary and other industry information.
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. For the NTLA price target at the top of this page, we present the average NTLA target price across the 6 analysts covering NTLA, as reported in data provided by Zacks …
Zacks Investment Research downgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a buy rating to a hold rating in a research note released on Wednesday morning, Zacks… Implied Volatility Surging for Intellia (NTLA) Stock Options Feb 07, 2020 · Investors in Intellia Therapeutics, Inc. NTLA need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 21, 2020 $17.50 Call had some of the
Zacks Investment Research cut shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a sell rating in a report published on Saturday morning, Zacks.com reports. According to Zacks, “Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system.
View Intellia Therapeutics, Inc. NTLA investment & stock information. Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Intellia Therapeutics, Inc. (NTLA) Stock Price, Quote ...
May 9, 2019 The company has also ventured into research reports for stocks, bonds, The U.S. stock fund method uses the same ranking system as Zacks' Intellia Therapeutics, Inc. - NTLA - Stock Price Today - Zacks View Intellia Therapeutics, Inc. NTLA investment & stock information. Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Intellia Therapeutics, Inc. (NTLA) Stock Price, Quote ... Find the latest Intellia Therapeutics, Inc. (NTLA) stock quote, history, news and other vital information to help you with your stock trading and investing. NTLA Stock Price, Forecast & News (Intellia Therapeutics) Intellia Therapeutics Inc (NASDAQ:NTLA) issued its quarterly earnings results on Thursday, February, 27th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.01.